AgonOx, MedImmune partner to develop cancer therapies
AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.
"We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx CEO Llew Keltner, M.D., Ph.D. "MedImmune has impressive capabilities in immuno-oncology, and we believe offers great potential for eventually bringing therapies utilizing the OX40 mechanism to trigger tumorspecific immune responses to patients."
MedImmune will also support further OX40 research at Providence Cancer Center, where the foundational preclinical and clinical development of OX40 has been conducted. Additional details of the agreement will not be disclosed.